NCT06881459Completed
The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 9 Sept 2025
Brief summary (registry, in English)
Investigating the effect of oxytocin on pancreatic endocrine functions by determining glucagon secretion during hypoglycemia in participants with type 1 diabetes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 11 Mar 2025
- Start date
- 25 Mar 2025
- Primary completion date
- 18 Jul 2025
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Diseases
- Type 1 diabetes
- NCT number
- NCT06881459
What you commit to
- Study type: Interventional
- Participants enrolled: 16
- From 25 Mar 2025 to the primary completion date, 18 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pituitary gland disease
- Any ongoing medication or physical or psychological condition that the investigator feels would interfere with trial participation
Lab values
- Anaemia (haemoglobin below normal range)
- Liver disease (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2 times normal values) or present hepatobiliary and/or gastrointestinal disorder(s)
- Kidney disease (serum creatinine above normal range)
- Long QTc on electrocardiogram (ECG) at screening (≥0.45 seconds)
- Treatment with any glucose-lowering drugs besides insulin
Other
- Late microvascular complications except mild non-proliferative retinopathy
- Regular tobacco smoking or use of other nicotine-containing products
Who the study is looking for
- Body mass index from 19 to 30 kg/m2
- T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c \<69 mmol/mol (\<8.5%)
- T1D duration of 3-30 years
- C-peptide negative (stimulated C-peptide ≤ 100 pmol/l)
- Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months
Age in the registry: 18 years to 70 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Clinical Metabolic Research, Gentofte Hospital Coordinator of this site? Confirm its status | Hellerup | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.